What specific financial data is presented in this 10-Q filing?

This 10-Q filing for the period ending June 29, 1998, would contain unaudited interim financial statements, including the balance sheet, statement of operations, and statement of cash flows for the quarter and year-to-date periods. It also includes management's discussion and analysis of financial condition and results of operations, and disclosures on any material changes in internal controls or risk factors.

What were Gilead's key products or pipeline developments around mid-1998?

While this specific filing doesn't detail product names, Gilead Sciences in 1998 was known for its antiviral drugs, particularly those targeting HIV/AIDS. Key developments around this time likely involved the progress of drugs like 'Viread' (tenofovir disoproxil fumarate) through clinical trials or early commercialization stages, and advancements in their nucleotide analog research.

How can investors assess the company's growth prospects based on this filing?

Investors can assess growth prospects by examining the trends in revenue and profitability, analyzing the investment in research and development as a percentage of revenue, and reviewing management's commentary on future outlook and pipeline progress. Significant increases in revenue or successful milestones in drug development would indicate positive growth potential.

Are there any significant risks or uncertainties mentioned in this 1998 filing?

Typical risks for a biotechnology company like Gilead in 1998 would include the lengthy and uncertain process of drug development and regulatory approval, dependence on a few key products, competition, patent expirations, and the ability to secure future funding for operations and research. The 'Risk Factors' section of the 10-Q would provide specific details on these potential challenges.

GILD 10-Q Quarterly Report Q2 FY1998 — Revenue, Net Income, EPS

Summary

Gilead Sciences, Inc. (GILD) filed its quarterly report (10-Q) for the period ending June 29, 1998, on August 11, 1998. This filing provides a snapshot of the company's financial performance and operational status during the second quarter of 1998. As a company focused on the development and commercialization of novel therapeutics, investors would be keen to understand its progress in clinical trials, any new product developments, and its overall financial health, including revenue, expenses, and cash flow. Given the historical context of this filing from 1998, it's important to note that Gilead was likely in a growth phase, with potential investments in research and development being a significant factor. Investors would be looking for indications of market traction for its existing products and the potential of its pipeline to drive future growth. The financial results presented would offer insights into the company's ability to manage its expenditures while advancing its scientific initiatives.

Key Highlights

1The filing is a 10-Q report for Gilead Sciences, Inc. (GILD) for the period ending June 29, 1998.
2The report was filed with the SEC on August 11, 1998.
3This document provides interim financial information for the second quarter of 1998.
4Investors can find information on Gilead's financial performance and operational status during this period.
5The filing is part of Gilead's regular reporting to shareholders and regulatory bodies.
6This report is a historical document, reflecting the company's situation in mid-1998.

GILEAD SCIENCES, INC. Quarterly Report for Q2 Ended Jun 30, 1998

Summary

Key Highlights

Frequently Asked Questions